×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NAMS – newamsterdam pharma company n.v. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NAMS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
08:05 am
nams
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
Low
Report
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
11/20
07:07 am
nams
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH [Yahoo! Finance]
High
Report
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH [Yahoo! Finance]
11/20
07:00 am
nams
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
High
Report
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
11/19
08:00 am
nams
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors
Medium
Report
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors
11/18
03:26 pm
nams
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 [Yahoo! Finance]
Low
Report
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 [Yahoo! Finance]
11/18
03:20 pm
nams
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
Low
Report
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
11/11
06:14 am
nams
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate [Yahoo! Finance]
Low
Report
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate [Yahoo! Finance]
11/7
08:36 am
nams
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
Medium
Report
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/20
07:07 am
nams
Form 8-K NewAmsterdam Pharma Co For: Nov 20
High
Report
Form 8-K NewAmsterdam Pharma Co For: Nov 20
11/19
04:15 pm
nams
Form 4 NewAmsterdam Pharma Co For: Nov 15 Filed by: Forbion Growth Management B.V.
High
Report
Form 4 NewAmsterdam Pharma Co For: Nov 15 Filed by: Forbion Growth Management B.V.
11/18
04:11 pm
nams
Form 8-K NewAmsterdam Pharma Co For: Nov 18
Medium
Report
Form 8-K NewAmsterdam Pharma Co For: Nov 18
11/15
04:36 pm
nams
Form 4 NewAmsterdam Pharma Co For: Nov 13 Filed by: Forbion Growth Management B.V.
Low
Report
Form 4 NewAmsterdam Pharma Co For: Nov 13 Filed by: Forbion Growth Management B.V.
11/15
04:30 pm
nams
Form SC 13D/A NewAmsterdam Pharma Co Filed by: Forbion Capital Fund IV Cooperatief U.A.
Low
Report
Form SC 13D/A NewAmsterdam Pharma Co Filed by: Forbion Capital Fund IV Cooperatief U.A.
11/14
05:46 pm
nams
Form SC 13G/A NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P.
Low
Report
Form SC 13G/A NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P.
11/13
04:24 pm
nams
Form 144 NewAmsterdam Pharma Co Filed by: NAP PoolCo B.V.
Low
Report
Form 144 NewAmsterdam Pharma Co Filed by: NAP PoolCo B.V.
11/6
08:01 am
nams
Form 10-Q NewAmsterdam Pharma Co For: Sep 30
High
Report
Form 10-Q NewAmsterdam Pharma Co For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: